Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins.

Yancey KB.

Dermatol Ther. 2014 Sep-Oct;27(5):311. doi: 10.1111/dth.12145. Epub 2014 Jul 12. No abstract available.

PMID:
25039296
2.

Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins.

Langenhan J, Dworschak J, Saschenbrecker S, Komorowski L, Schlumberger W, Stöcker W, Westermann J, Recke A, Zillikens D, Schmidt E, Probst C.

Exp Dermatol. 2014 Apr;23(4):253-9. doi: 10.1111/exd.12355.

PMID:
24533885
3.

Advances in pemphigus and its endemic pemphigus foliaceus (Fogo Selvagem) phenotype: a paradigm of human autoimmunity.

Culton DA, Qian Y, Li N, Rubenstein D, Aoki V, Filhio GH, Rivitti EA, Diaz LA.

J Autoimmun. 2008 Dec;31(4):311-24. doi: 10.1016/j.jaut.2008.08.003. Epub 2008 Oct 5. Review.

4.

What are the "true" pathogenic anti-desmoglein antibodies?

Muro Y, Sugiura K, Akiyama M.

Acta Derm Venereol. 2015 Sep;95(7):872, 874. doi: 10.2340/00015555-2119. No abstract available.

5.

Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.

Eming R, Rech J, Barth S, Kalden JR, Schuler G, Harrer T, Hertl M.

Dermatology. 2006;212(2):177-87.

PMID:
16484825
6.

A case of pemphigus herpetiformis with absence of antibodies to desmogleins 1 and 3.

Miura T, Kawakami Y, Oyama N, Ohtsuka M, Suzuki Y, Ohyama B, Hashimoto T, Motoki Y, Yamamoto T.

J Eur Acad Dermatol Venereol. 2010 Jan;24(1):101-3. No abstract available.

PMID:
20050294
7.

Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber.

Lüftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M.

Br J Dermatol. 2003 Sep;149(3):598-605.

PMID:
14510995
8.

Is there an emergent need to modify the desmoglein compensation theory in pemphigus on the basis of Dsg ELISA data and alternative pathogenic mechanisms?

Sardana K, Garg VK, Agarwal P.

Br J Dermatol. 2013 Mar;168(3):669-74. doi: 10.1111/bjd.12012. Epub 2012 Nov 2. No abstract available.

PMID:
22913529
9.

Rituximab in pemphigus foliaceous with autoantibodies against both Desmoglein 1 and Desmoglein 3.

Carvalho R, Maio P, Cunha D, Freitas I, Afonso A, Cardoso J.

Eur J Dermatol. 2011 May-Jun;21(3):415-6. doi: 10.1684/ejd.2011.1288. No abstract available.

PMID:
21527367
10.

Pemphigus vegetans Neumann type with anti-desmoglein and anti-periplakin autoantibodies.

Cozzani E, Christana K, Mastrogiacomo A, Rampini P, Drosera M, Casu M, Murialdo G, Parodi A.

Eur J Dermatol. 2007 Nov-Dec;17(6):530-3. Epub 2007 Oct 19.

PMID:
17951135
11.

In vitro pathogenicity assay for anti-desmoglein autoantibodies in pemphigus.

Ishii K, Amagai M.

Methods Mol Biol. 2013;961:219-25. doi: 10.1007/978-1-62703-227-8_13.

PMID:
23325646
12.

Smaller desmosomes are seen in the skin of pemphigus patients with anti-desmoglein 1 antibodies but not in patients with anti-desmoglein 3 antibodies.

van der Wier G, Pas HH, Kramer D, Diercks GF, Jonkman MF.

J Invest Dermatol. 2014 Aug;134(8):2287-90. doi: 10.1038/jid.2014.140. Epub 2014 Mar 12. No abstract available.

13.

Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab.

Pfütze M, Eming R, Kneisel A, Kuhlmann U, Hoyer J, Hertl M.

Dermatology. 2009;218(3):237-45. doi: 10.1159/000187431. Epub 2008 Dec 16.

PMID:
19088461
14.

Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.

Nagasaka T, Fujii Y, Ishida A, Handa M, Tanikawa A, Amagai M, Nishikawa T.

Br J Dermatol. 2008 Apr;158(4):685-90. doi: 10.1111/j.1365-2133.2007.08416.x. Epub 2008 Jan 30.

PMID:
18241273
15.

Desmoglein ELISA in the diagnosis of pemphigus and its correlation with the severity of pemphigus vulgaris.

Mortazavi H, Shahdi M, Amirzargar AA, Naraghi ZS, Valikhani M, Daneshpazhooh M, Vasheghani-Farahani A, Sedaghat M, Chams-Davatchi C.

Iran J Allergy Asthma Immunol. 2009 Mar;8(1):53-6. doi: 08.01/ijaai.5356.

16.

Recalcitrant facial pemphigus vulgaris: correlation of skin lesions with the ratio of antidesmoglein antibodies 1 and 3.

Fujii M, Honma M, Iinuma S, Kaneta K, Komatsu S, Sato K, Takahashi H, Ishida-Yamamoto A, Iizuka H.

Clin Exp Dermatol. 2011 Apr;36(3):284-7. doi: 10.1111/j.1365-2230.2010.03920.x. Epub 2010 Sep 16.

PMID:
21418270
17.

Frequency of shifts over time in the profile of antidesmoglein antibodies in pemphigus vulgaris.

Weitz D, Bystryn JC.

Arch Dermatol. 2007 Aug;143(8):1073-4. No abstract available.

PMID:
17709673
18.

Screening and analysis of adsorbents for pemphigus autoantibodies.

Yamada H, Itoh A, Hatanaka Y, Tsukiji M, Takamori K.

Ther Apher Dial. 2010 Jun;14(3):292-7. doi: 10.1111/j.1744-9987.2010.00827.x.

PMID:
20609181
19.

IgG/IgA pemphigus recognizing desmogleins 1 and 3 in a patient with Sjögren's syndrome.

Furuya A, Takahashi E, Ishii N, Hashimoto T, Satoh T.

Eur J Dermatol. 2014 Jul-Aug;24(4):512-3. doi: 10.1684/ejd.2014.2391. No abstract available.

PMID:
25167567
20.

Orodigital pemphigus vulgaris: a pathogenic role of anti-desmoglein-3 autoantibodies in pemphigus paronychia?

Laffitte E, Panizzon RG, Borradori L.

Dermatology. 2008;217(4):337-9. doi: 10.1159/000155645. Epub 2008 Sep 18.

PMID:
18799879
Items per page

Supplemental Content

Write to the Help Desk